

# Olin Corp

# Reiterating Buy as chlor-alkali prices start improving; watch Red Sea for epoxies

Reiterate Rating: BUY | PO: 69.00 USD | Price: 55.15 USD

# Olin sees recovery ahead, reiterating Buy

While OLN's 4Q23 EBITDA of \$210mn was short of our \$235mn forecast on lower chlor-alkali earnings, the highlight of the earnings release in our view was the company's outlook that EBITDA will be higher in 2024 vs 2023 – something we previously saw as a tall order given elevated profitability at the start of last year (e.g, 1Q23 EBITDA was \$434mn). Winchester looks to be doing better, and while we're trimming our Epoxy earnings, we are encouraged that management does expect a meaningful rebound (albeit off recent EBITDA losses) this year. Additionally, OLN highlighted that caustic prices are now in an upswing, and its own chlorine realizations should increase vs Q4 at least due to some contract renegotiations. There was less said about volumes and inventories across the supply chain, but our understanding is that both have also troughed. As such we raise our 2024E EBITDA to \$1.31bn (flat y/y) from \$1.23bn. We reiterate our Buy rating with a \$69 PO (raised from \$63 to reflect our higher 2024E estimates).

# Watch for "escape velocity" in EPS

OLN's share count has declined by ~10% in each of the past two years, and now stands at ~124mn vs ~163mn at the end of 2021. This trend is poised to continue: with almost \$600mn in 2024 FCF by our estimate (guidance \$545mn+) and no urgent need to delever. We expect the company to allocate over \$0.5bn to buybacks this year and an increased sum as its earnings recover. Perhaps investors have been less focused on this aspect of the investment thesis given OLN's earnings challenges, but as profitability recovers the buyback accretion should become evident. For example, our 2025E EPS of \$8.95 would be a record high, topping 2021's \$8.94 despite adj. net income still being ~25% lower. In other words, the per share earnings can recover well before EBITDA.

# **Epoxies highly levered to Red Sea disruptions**

We model \$99mn in 2024 Epoxy EBITDA vs \$143mn previously as we take a more conservative stance at the start of the year. However, epoxies are the chemistry likely to be most affected by continued disruption in the Red Sea, with Europe importing almost 50% of its needs per ICIS data. Spot prices are already moving higher and OLN noted that it too is seeing improved pricing. Moreover, given OLN's significant pull back in operating rates, any volume benefits should come with sizable incremental margins.

Estimates (Dec) (US\$)	2022A	2023A	2024E	2025E	2026E
EPS	8.75	3.81	3.70	8.95	12.55
GAAP EPS	8.94	3.51	3.70	8.95	12.55
EPS Change (YoY)	15.7%	-56.5%	-2.9%	141.9%	40.2%
Consensus EPS (Bloomberg)			3.79	6.41	6.32
DPS	0.80	0.80	0.80	0.80	0.80
Valuation (Dec)					
P/E	6.3x	14.5x	14.9x	6.2x	4.4x
GAAP P/E	6.2x	15.7x	14.9x	6.2x	4.4x
Dividend Yield	1.5%	1.5%	1.5%	1.5%	1.5%
EV / EBITDA*	3.9x	7.3x	7.3x	4.8x	4.3x
Free Cash Flow Yield*	24.1%	10.5%	8.3%	15.4%	19.4%
* For full definitions of <i>IQ</i> method <sup>SM</sup> measures, see page 5.					

BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 6 to 8. Analyst Certification on page 4. Price Objective Basis/Risk on page 4.

Timestamp: 28 January 2024 09:46PM EST

#### 28 January 2024

### Equity

Key Changes		
(US\$)	Previous	Current
Price Obj.	63.00	69.00
2024E Rev (m)	6,885.4	6,909.5
2025E Rev (m)	7,947.5	7,931.3
2026E Rev (m)	NA	8,271.4
2024E EPS	3.25	3.70
2025E EPS	8.75	8.95
2026E EPS	NA	12.55

### Steve Byrne, CFA

Research Analyst BofAS +1 646 855 5746 steve.byrne@bofa.com

### Salvator Tiano, CFA

Research Analyst BofAS +1 646 855 5904 salvator.tiano@bofa.com

# Rock Hoffman

Research Analyst BofAS +1 917 565 6205 rock.hoffman@bofa.com

### **Stock Data**

Price	55.15 USD
Price Objective	69.00 USD
Date Established	28-Jan-2024
Investment Opinion	C-1-7
52-Week Range	41.71 USD - 64.70 USD
Mrkt Val (mn) / Shares Out	7,004 USD / 127.0
(mn)	
Free Float	99.3%
Average Daily Value (mn)	63.57 USD
BofA Ticker / Exchange	OLN / NYS
Bloomberg / Reuters	OLN US / OLN.N
ROE (2024E)	20.7%
Net Dbt to Eqty (Dec-2023A)	112.0%
ESGMeter™	Medium

ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of BofA Global Research's equity investment rating, volatility risk rating, income rating, and price objective for that company. For full details, refer to "BofA ESGMeter Methodology".

Jargon buster:

EPI: Epichlorohydrin

# **iQ**profile<sup>™</sup>Olin Corp

(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Return on Capital Employed	20.8%	9.8%	9.3%	18.1%	21.5%
Return on Equity	50.0%	20.6%	20.7%	47.7%	56.9%
Operating Margin	19.5%	11.4%	11.5%	18.5%	20.8%
Free Cash Flow	1,685	738	583	1,078	1,360
<i>iQ</i> method <sup>™</sup> – <b>Quality of Earnings*</b>					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Cash Realization Ratio	1.5x	2.0x	1.9x	1.4x	1.4x
Asset Replacement Ratio	0.4x	0.4x	0.5x	0.5x	0.6x
Tax Rate	23.0%	19.6%	27.5%	25.0%	25.0%
Net Debt-to-Equity Ratio	93.8%	112.0%	122.4%	126.4%	103.8%
Interest Cover	12.9x	4.4x	4.4x	8.2x	9.9x
Income Statement Data (Dec)					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Sales	9,376	6,833	6,909	7,931	8,271
% Change	5.2%	-27.1%	1.1%	14.8%	4.3%
Gross Profit	2,822	1,717	1,704	2,394	2,637
% Change	-3.0%	-39.1%	-0.8%	40.5%	10.2%
EBITDA	2,428	1,310	1,310	1,974	2,224
% Change	-2.6%	-46.0%	0%	50.7%	12.7%
Net Interest & Other Income	(142)	(177)	(179)	(180)	(175)
Net Income (Adjusted)	1,298	491	444	964	1,161
% Change	5.5%	-62.2%	-9.5%	117.0%	20.4%
Free Cash Flow Data (Dec)					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Net Income from Cont Operations (GAAP)	1,326	452	444	964	1,161
Depreciation & Amortization	599	533	518	509	501
Change in Working Capital	62	57	(24)	(139)	(45)
Deferred Taxation Charge	(32)	(56)	(61)	19	23
Other Adjustments, Net	(33)	(13)	(55)	(275)	0
Capital Expenditure	(237)	(236)	(240)	(275)	(280)
Free Cash Flow	1,685	738	583	1,078	1,360
Free Cash Flow % Change	1,685 9.4%	738 -56.2%	583 -21.1%	1,078 85.1%	1,360 26.1%
Free Cash Flow % Change Share / Issue Repurchase	<b>1,685 9.4%</b> (1,351)	<b>738</b> - <b>56.2%</b> (711)	<b>583</b> <b>-21.1%</b> (550)	<b>1,078 85.1%</b> (1,000)	<b>1,360 26.1%</b> (1,000)
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid	1,685 9.4% (1,351) (116)	<b>738 -56.2%</b> (711) (57)	<b>583 -21.1%</b> (550) (96)	1,078 85.1% (1,000) (86)	<b>1,360 26.1%</b> (1,000) (74)
Free Cash Flow % Change Share / Issue Repurchase	<b>1,685 9.4%</b> (1,351)	<b>738</b> - <b>56.2%</b> (711)	<b>583</b> <b>-21.1%</b> (550)	<b>1,078 85.1%</b> (1,000)	<b>1,360 26.1%</b> (1,000)
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec)	1,685 9.4% (1,351) (116) (201)	<b>738 -56.2%</b> (711) (57) 86	<b>583 -21.1%</b> (550) (96) 0	1,078 85.1% (1,000) (86)	1,360 26.1% (1,000) (74) (100)
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions)	1,685 9.4% (1,351) (116) (201)	738 -56.2% (711) (57) 86	583 -21.1% (550) (96) 0	1,078 85.1% (1,000) (86) 0	1,360 26.1% (1,000) (74) (100)
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents	1,685 9.4% (1,351) (116) (201) 2022A 194	738 -56.2% (711) (57) 86 2023A	583 -21.1% (550) (96) 0	1,078 85.1% (1,000) (86) 0	1,360 26.1% (1,000) (74) (100) 2026E 391
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables	1,685 9.4% (1,351) (116) (201) 2022A 194 925	738 -56.2% (711) (57) 86 2023A 170 875	583 -21.1% (550) (96) 0 2024E 142 912	1,078 85.1% (1,000) (86) 0	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038	738 -56.2% (711) (57) 86 2023A 170 875 928	583 -21.1% (550) (96) 0 2024E 142 912 893	1,078 85.1% (1,000) (86) 0 2025E 169 1,000 949	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241	1,078 85.1% (1,000) (86) 0 2025E 169 1,000 949 2,007	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337	1,078 85.1% (1,000) (86) 0 2025E 169 1,000 949 2,007 3,317	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Total Assets	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525	1,078 85.1% (1,000) (86) 0 2025E 169 1,000 949 2,007 3,317 7,442	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Total Assets Short-Term Debt	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713 79	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525 79	1,078 85.1% (1,000) (86) 0  2025E 169 1,000 949 2,007 3,317 7,442 79	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Total Assets Short-Term Debt Other Current Liabilities	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044 10 1,552	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713 79 1,449	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525 79 1,428	1,078 85.1% (1,000) (86) 0  2025E 169 1,000 949 2,007 3,317 7,442 79 1,432	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477 79
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Total Assets Short-Term Debt Other Current Liabilities Long-Term Debt	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044 10 1,552 2,571	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713 79 1,449 2,591	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525 79 1,428 2,591	1,078 85.1% (1,000) (86) 0  2025E 169 1,000 949 2,007 3,317 7,442 79 1,432 2,591	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477 79 1,446 2,491
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Short-Term Debt Other Current Liabilities Long-Term Debt Other Non-Current Liabilities	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044 10 1,552 2,571 1,368	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713 79 1,449 2,591 1,325	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525 79 1,428 2,591 1,325	1,078 85.1% (1,000) (86) 0  2025E 169 1,000 949 2,007 3,317 7,442 79 1,432 2,591 1,325	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477 79 1,446 2,491 1,325
Free Cash Flow % Change Share / Issue Repurchase Cost of Dividends Paid Change in Debt  Balance Sheet Data (Dec) (US\$ Millions) Cash & Equivalents Trade Receivables Other Current Assets Property, Plant & Equipment Other Non-Current Assets Total Assets Short-Term Debt Other Current Liabilities Long-Term Debt	1,685 9.4% (1,351) (116) (201) 2022A 194 925 1,038 2,674 3,214 8,044 10 1,552 2,571	738 -56.2% (711) (57) 86  2023A 170 875 928 2,520 3,220 7,713 79 1,449 2,591	583 -21.1% (550) (96) 0  2024E 142 912 893 2,241 3,337 7,525 79 1,428 2,591	1,078 85.1% (1,000) (86) 0  2025E 169 1,000 949 2,007 3,317 7,442 79 1,432 2,591	1,360 26.1% (1,000) (74) (100) 2026E 391 1,042 965 1,786 3,294 7,477 79 1,446 2,491

# **Company Sector**

Chemicals-Specialty

# **Company Description**

Olin is a US-based company with \$6.9bn in 2023 sales from three segments: Chlor Alkali (60% of sales), Epoxy (20%) and Winchester (20%). OLN is the largest global producer of chlorine and caustic soda. Winchester produces small caliber ammunition for commercial, military, law and enforcement. OLN became the largest global producer of chlor-alkali following the transformative acquisition of DOW's Chlorine Business in 2015, tripling its chlor-alkali capacity and adding its Epoxy business.

#### **Investment Rationale**

Olin has shown extraordinary leverage to a rebound in its underlying commodity markets. While some of this rebound is undoubtedly cycle driven, and thus potentially a source of eventual downside risk, we believe much can also be attributed to management intervention in the business. While we do see risks to numbers, we believe current valuations more than compensate investors for said risk. We rate shares Buy accordingly.

### **Stock Data**

Average Daily Volume

# **Quarterly Earnings Estimates**

	2023	2024
Q1	1.50A	0.38E
Q2	1.08A	0.80E
Q3	0.89A	1.19E
04	0.28A	1 36F

1,208,209

# **Exhibit 1: Olin Income Statement Summary** We raise our 2024E EBITDA to \$1,310mn

Net Sales	2021	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24E	2Q24E	3Q24E	4Q24E	2024E	2025E
Chlor-Alkali	\$4,141	\$5,085	\$1,117	\$1,002	\$970	\$906	\$3,995	\$916	\$952	\$1,047	\$997	\$3,912	\$4,421
Ероху	3,186	2,691	361	334	322	313	1,329	335	334	354	351	1,374	1,854
Winchester	1,584	1,601	367	367	380	395	1,509	403	411	411	399	1,624	1,656
Consolidated Net Sales	8,911	9,376	1,844	1,703	1,671	1,615	6,833	1,655	1,697	1,812	1,747	6,909	7,931
Change	55%	5%	-25%	-35%	-28%	-18%	-27%	-10%	0%	8%	8%	1%	15%
3													
EBITDA													
Chlor-Alkali	1,464	1,664	360	293	280	171	1,104	185	234	275	308	1,002	1,493
Epoxy	704	472	36	15	(14)	(10)	26	2	22	41	33	99	266
Winchester	435	397	67	71	71	74	283	80	82	79	75	315	326
Corporate & Other	(111)	(105)	(29)	(28)	(22)	(25)	(103)	(28)	(28)	(25)	(26)	(107)	(112)
Total	2,493	2,428	434	351	315	210	1,310	239	310	370	391	1,310	1,974
Operating Income Before Unusual Items													
Chlor-Alkali	998	1,181	246	180	172	66	664	78	127	168	201	574	1,073
Epoxy	617	389	21	(1)	(29)	(23)	(31)	(12)	7	27	21	43	212
Winchester	412	373	61	65	65	65	256	74	76	72	67	289	300
Corporate & Other	(116)	(114)	(31)	(30)	(24)	(27)	(112)	(30)	(30)	(27)	(28)	(115)	(120)
Consolidated Operating Income Before Unusual Items	1,910	1,829	297	214	184	82	777	110	180	240	261	791	1,465
Change	2751%	-4%					-58%					2%	85%
Interest Expense	348	142	41	44	45	46	177	45	45	44	45	179	180
Other Expense (Income)	0	0	0	0	0	0	0	0	0	0	0	0	0
Pretax Income	1,563	1,687	256	170	139	36	600	65	135	196	217	613	1,285
Income Taxes	331	389	56	31	25	5	117	18	37	54	60	169	321
Tax Rate	21.2%	23.0%	21.9%	18.4%	18.1%	14.1%	19.6%	27.5%	27.5%	27.5%	27.5%	27.5%	25.0%
Minority Interest	0	23.0 /0	(2)	(2)	0.170	(4)	(8)	27.570	0	0	27.570	0	0
Income Before Nonrecurring items	1,231	1,298	202	141	113	35	491	47	98	142	157	444	964
Nonrecurring Items	64	28	(46)	6	(9)	18	(30)	0	0	0	0	0	0
Net Income	1,295	1,326	156	147	105	53	461	47	98	142	157	444	964
The meaning	.,	1,0_0	.50		.05	33			30		.57		
Diluted EPS Before Nonrecurring	\$7.56	\$8.65	\$1.50	\$1.08	\$0.89	\$0.28	\$3.76	\$0.38	\$0.80	\$1.19	\$1.36	\$3.70	\$8.95
Change Before Gains/(Charges)	-420%	14%	-40%	-61%	-53%	-81%	-57%	-75%	-26%	34%	385%	-1%	142%
Diluted Shares Outstanding (Million)	162.8	148.4	134.4	130.4	127.0	123.5	128.8	123.2	121.8	119.2	115.5	119.9	107.7
Segment Sales Growth: Chlor-Alkali	39.9%	22.8%	-10.3%	20.60/-	22.20/-	-22.7%	-21.4%	-18.0%	-5.0%	8.0%	10.0%	-2.1%	13.0%
	70.3%	-15.6%	-54.3%	-28.6% -56.8%	-23.3% -50.1%	-35.3%	-21.4% -50.6%	-7.0%	0.0%	10.0%	12.0%	3.3%	35.0%
Epoxy Winchester	70.3%	1.1%			-8.2%	23.6%	-5.7%	10.0%	12.0%	8.0%	12.0%	7.6%	2.0%
Willchestel	70.070	1.170	-14.1%	-10.7%	-0.2 %	23.0%	-3.770	10.0%	12.0%	0.0%	1.0%	7.070	2.0%
EBITDA Margins Before Special Items													
Chlor-Alkali	35.4%	32.7%	32.2%	29.3%	28.8%	18.9%	27.6%	20.2%	24.6%	26.2%	30.9%	25.6%	33.8%
Ероху	22.1%	17.5%	10.0%	4.4%	-4.4%	-3.2%	2.0%	0.6%	6.7%	11.7%	9.5%	7.2%	14.4%
Winchester	27.5%	24.8%	18.3%	19.4%	18.7%	18.6%	18.7%	19.8%	19.9%	19.3%	18.7%	19.4%	19.7%
Total	28.0%	25.9%	23.5%	20.6%	18.9%	13.0%	19.2%	14.5%	18.3%	20.4%	22.4%	19.0%	24.9%
Operating Margins Before Items			22.25	10.00	17.00	70-1		0 ==:	10.00	16.00	20.25		
Chlor-Alkali	24.1%	23.2%	22.0%	18.0%	17.8%	7.3%	16.6%	8.5%	13.3%	16.0%	20.2%	14.7%	24.3%
Epoxy	19.4%	14.4%	5.9%	-0.1%	-9.0%	-7.4%	-2.3%	-3.6%	2.2%	7.7%	5.9%	3.1%	11.4%
Winchester	26.0%	23.3%	16.6%	17.6%	17.0%	16.5%	16.9%	18.3%	18.4%	17.6%	16.9%	17.8%	18.1%
Consolidated Operating Income Before Unusual Items	21.4%	19.5%	16.1%	12.6%	11.0%	5.1%	11.4%	6.7%	10.6%	13.3%	15.0%	11.5%	18.5%

**Source:** Company Reports and BofA Global Research Estimates

BofA GLOBAL RESEARCH



# Price objective basis & risk

## Olin Corp (OLN)

Our \$69 price objective is based on a 8x 2024E EV/EBITDA multiple. This is slightly above the average 5 year forward EBITDA multiple for OLN. We see the premium as warranted, given that earnings are expected to remain at trough levels in 2024.

Upside risks to our PO are a further acceleration in caustic soda, chlorine and EDC pricing, higher than expected demand growth, lower natural gas prices, and a faster than expected recovery in Epoxy segment earnings. Downside risks to our PO are the potential for near-term caustic price headwinds and EDC price headwinds, higher natural gas prices and a slower than expected recovery in Epoxy earnings.

# **Analyst Certification**

I, Steve Byrne, CFA, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

**US - Chemicals Coverage Cluster** 

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
BUY				
	Axalta Coating Systems	AXTA	AXTA US	Steve Byrne, CFA
	Bunge Limited	BG	BG US	Salvator Tiano, CFA
	CF Industries	CF	CF US	Steve Byrne, CFA
	Dow Inc	DOW	DOW US	Steve Byrne, CFA
	Eastman Chemical Co	EMN	EMN US	Salvator Tiano, CFA
	Element Solutions Inc.	ESI	ESI US	Steve Byrne, CFA
	Green Plains	GPRE	GPRE US	Salvator Tiano, CFA
	Huntsman Corp	HUN	HUN US	Salvator Tiano, CFA
	Linde	LIN	LIN US	Steve Byrne, CFA
	Linde	LINGY	LIN GY	Steve Byrne, CFA
	Nutrien	NTR	NTR US	Steve Byrne, CFA
	Olin Corp	OLN	OLN US	Steve Byrne, CFA
	PPG Industries Inc.	PPG	PPG US	Steve Byrne, CFA
	Sigma Lithium	SGML	SGML US	Steve Byrne, CFA
	The Mosaic Company	MOS	MOS US	Steve Byrne, CFA
NEUTRAL				
RECTION	Air Products	APD	APD US	Steve Byrne, CFA
	Albemarle	ALB	ALB US	Steve Byrne, CFA
	Archer-Daniels-Midland Company	ADM	ADM US	Salvator Tiano. CFA
	Corteva	CTVA	CTVA US	Steve Byrne, CFA
	Fcolab Inc	ECL	ECL US	Steve Byrne, CFA
	International Flavors & Fragrances	IFF	IFF US	Salvator Tiano, CFA
	LyondellBasell Industries	LYB	LYB US	Steve Byrne, CFA
	Origin Materials	ORGN	ORGN US	Steve Byrne, CFA
	Oligin Materials	ORGIN	ONUNUS	Steve by me, ci A
UNDERPERFORM				
	Celanese Corporation	CE	CE US	Salvator Tiano, CFA
	DuPont	DD	DD US	Steve Byrne, CFA
	FMC Corporation	FMC	FMC US	Steve Byrne, CFA
	RPM International Inc	RPM	RPM US	Steve Byrne, CFA
	Sherwin-Williams Company	SHW	SHW US	Steve Byrne, CFA
	Westlake Chemical Partners, LP	WLKP	WLKP US	Steve Byrne, CFA
	Westlake Corp	WLK	WLK US	Steve Byrne, CFA



# **IQ**method<sup>™</sup> Measures Definitions

Business Performance	Numerator	Denominator
Return On Capital Employed	NOPAT = (EBIT + Interest Income) × (1 - Tax Rate) + Goodwill Amortization	Total Assets – Current Liabilities + ST Debt + Accumulated Goodwill
		Amortization
Return On Equity	Net Income	Shareholders' Equity
Operating Margin	Operating Profit	Sales
Earnings Growth	Expected 5 Year CAGR From Latest Actual	N/A
Free Cash Flow	Cash Flow From Operations — Total Capex	N/A
Quality of Earnings	Numerator	Denominator
Cash Realization Ratio	Cash Flow From Operations	Net Income
Asset Replacement Ratio	Capex	Depreciation
Tax Rate	Tax Charge	Pre-Tax Income
Net Debt-To-Equity Ratio	Net Debt = Total Debt - Cash & Equivalents	Total Equity
Interest Cover	EBIT	Interest Expense
Valuation Toolkit	Numerator	Denominator
Price / Earnings Ratio	Current Share Price	Diluted Earnings Per Share (Basis As Specified)
Price / Book Value	Current Share Price	Shareholders' Equity / Current Basic Shares
Dividend Yield	Annualised Declared Cash Dividend	Current Share Price
Free Cash Flow Yield	Cash Flow From Operations – Total Capex	Market Cap = Current Share Price × Current Basic Shares
Enterprise Value / Sales	EV = Current Share Price × Current Shares + Minority Equity + Net Debt +	Sales
,	Other LT Liabilities	

EV / EBITDA Enterprise Value Basic EBIT + Depreciation + Amortization

\*\*Menethod 3\*\*\*is the set of BofA Global Research standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.


\*\*Redatabase\*\* is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Global Research.

**IQ**profile<sup>≤M</sup>, **IQ**method<sup>≤M</sup> are service marks of Bank of America Corporation. **IQ**database® is a registered service mark of Bank of America Corporation.

# **Disclosures**

# **Important Disclosures**

### Olin Corp (OLN) Price Chart



B: Buy, N: Neutral, U: Underperform, PO: Price Objective, NA: No longer valid, NR: No Rating

The Investment Opinion System is contained at the end of the report under the heading "Fundamental Equity Opinion Key". Dark grey shading indicates the security is restricted with the opinion suspended. Medium grey shading indicates the security is under review with the opinion withdrawn. Light grey shading indicates the security is not covered. Chart is current as of a date no more than one trading day prior to the date of the report.

#### Equity Investment Rating Distribution: Chemicals Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	66	47.83%	Buy	33	50.00%
Hold	33	23.91%	Hold	16	48.48%
Sell	39	28.26%	Sell	20	51.28%

### Equity Investment Rating Distribution: Global Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	1895	53.62%	Buy	1083	57.15%
Hold	832	23.54%	Hold	454	54.57%
Sell	807	22.84%	Sell	383	47.46%

R1 Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

# Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster<sup>R2</sup>

Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
nderperform	N/A	≥ 20%

R2Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the Price Charts website, or call 1-800-MERRILL to have them mailed. BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Olin Corp.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Olin Corp.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Olin Corp.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Olin Corp.

The issuer is a runge within the last 12 months a securities business client (non-investment backing) of PofAS and/or one or more of its affiliate.

The issuer is or was, within the last 12 months, a securities business client (non-investment banking) of BofAS and/or one or more of its affiliates: Olin Corp.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.



# **Other Important Disclosures**

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch (Hong Kong): Merrill (Hong Kong): Merr (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Mexico): Merrill Ly de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch (Israel): Merrill Lynch (Israel) intended by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information in Germany and is regulated by Merrill Lynch (DIFC) is done so in accor

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

### General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such



securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

### BofA ESGMeter Methodology:

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at BofA ESGMeter methodology. ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

### Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public inform

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

